Animal Antibiotics Antimicrobials Market Report 2026

The animal antibiotics antimicrobials market size has grown strongly in recent years. It will grow from $4.36 billion in 2025 to $4.59 billion in 2026 at a compound annual growth rate (CAGR) of 5.4%. The growth in the historic period can be attributed to rising livestock disease outbreaks, increasing demand for animal protein production, widespread use of antibiotics in animal farming, limited veterinary healthcare infrastructure in developing regions, growth in intensive farming practices.

The animal antibiotics antimicrobials market size is expected to see strong growth in the next few years. It will grow to $5.73 billion by 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to tightening global antimicrobial resistance regulations, increasing shift toward sustainable livestock farming, rising adoption of veterinary preventive healthcare programs, expansion of precision animal health solutions, growing awareness of food safety and zoonotic disease control. Major trends in the forecast period include increasing adoption of precision veterinary antimicrobial therapies, rising focus on antimicrobial resistance mitigation in animal health, expansion of preventive livestock disease management programs, growth in antibiotic stewardship regulations in veterinary medicine, increasing demand for alternative non antibiotic growth promoters in animal husbandry.

The increasing incidence of animal diseases is expected to drive the growth of the animal antibiotics antimicrobials market in the future. Animal diseases refer to infections and health conditions caused by bacteria, viruses, parasites, or fungi that impact livestock and companion animals and reduce their productivity and overall well-being. The increase in incidence of animal diseases is attributed to the geographic expansion of infectious diseases into new regions and species. Animal antibiotics antimicrobials help reduce the burden of animal diseases by enabling effective treatment of infections, improving recovery rates, and minimizing disease transmission among animal populations. For instance, in May 2025, according to the World Organization for Animal Health, a France-based animal health organization, outbreaks of avian influenza in mammals rose significantly from 459 outbreaks in 2023 to 1,022 outbreaks in 2024 across 55 countries, indicating a sharp increase in disease spread. Therefore, the increasing incidence of animal diseases is driving the growth of the animal antibiotics antimicrobials market.

Leading companies operating in the animal antibiotics antimicrobials market are focusing on developing innovative products, such as long-acting injectable antibiotics, to enhance treatment compliance and therapeutic effectiveness. A long-acting injectable antibiotic is a sustained-release antimicrobial formulation administered via injection that maintains therapeutic drug levels over an extended period, reducing the need for repeated dosing. For example, in November 2025, Dechra Pharmaceuticals, a UK-based veterinary pharmaceuticals company, launched Solovecin. The product delivers a complete course of antibiotic therapy in a single in-clinic injection, addressing common compliance challenges associated with oral dosing in pets. It enhances treatment reliability and supports antimicrobial stewardship by reducing missed doses and incomplete therapy.

In August 2024, Zoetis Inc., a US-based provider of veterinary pharmaceuticals, vaccines, diagnostics, and animal health solutions, partnered with the Responsible Use of Medicines Alliance Companion Animal and Equine to support antimicrobial stewardship initiatives. Through this agreement, the collaboration aims to reinforce responsible antibiotic use practices, improve awareness of antimicrobial resistance, and encourage the sustainable use of veterinary antibiotics via industry-wide engagement. Responsible Use of Medicines Alliance Companion Animal and Equine is a UK-based alliance that promotes the responsible use of medicines in companion animals and equines through education, stewardship campaigns, and industry collaboration.

Major companies operating in the animal antibiotics antimicrobials market are Merck & Co. Inc., Boehringer Ingelheim GmbH, Zoetis Inc., Zydus Lifesciences Limited, Ceva Santé Animale, Virbac S. A., Phibro Animal Health Corporation, Dechra Pharmaceuticals PLC, Neogen Corporation, China Animal Husbandry Industry Co. Ltd., HIPRA S. A., Vetoquinol S. A., Norbrook Laboratories Limited, Indian Immunologicals Limited, American Regent Inc., ECO Animal Health Group plc, Elanco Animal Health Incorporated, Bioveta a. s., Huvepharma EOOD, Inovet BV, Ashish Life Science Pvt. Ltd., Kyoritsu Seiyaku Corporation, UCBVET Saúde Animal Ltda, Lutim Pharma Private Limited.

North America was the dominating region in the animal antibiotics antimicrobials market in 2025. Asia-Pacific is expected to be the rapidly expanding region during the forecast period. The regions covered in the animal antibiotics antimicrobials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the animal antibiotics antimicrobials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The animal antibiotics antimicrobials market consists of sales of products such as aminoglycosides, chloramphenicol, glycopeptides, pleuromutilins, carbapenems, polymyxins, nitrofurans, ionophores, rifamycins, oxazolidinones, streptogramins, and fusidic acid derivatives. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.